Transcutaneous electrical cranial-auricular acupoints stimulation (TECAS) for treatment of the depressive disorder with insomnia as the complaint (DDI): A case series

Yu-hong, Zhao; Xiao, Xue; Li, Shaoyuan; Zhang, Shuai; Zhang, Jinling; He, Jia-Kai; Hou, Xiyong; Tian, Jing; Zhai, Wei-Hang; Wang, Yu; Rong, Peijing

doi:10.1016/j.brs.2022.01.018

Cited by 7 publications

(7 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It could generate therapeutic potentials of the two cranial nerve stimulations in an additive or even synergistic manner. Our case study has observed a robust therapeutic response to TECAS in patients with comorbid depression and insomnia 33 …”

Section: Figmentioning

confidence: 76%

“…Our case study has observed a robust therapeutic response to TECAS in patients with comorbid depression and insomnia. 33 We hence hypothesized that TECAS was comparable to antidepressants in improving depression, with a better safety profile. To test this hypothesis, an assessor-blinded, randomized, non-inferiority trial was conducted to compare the efficacy and safety profile of TECAS and escitalopram, a commonly used antidepressant in patients with MDD.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Transcutaneous electrical cranial‐auricular acupoint stimulation versus escitalopram for mild‐to‐moderate depression: An assessor‐blinded, randomized, non‐inferiority trial

Zhang

Yang

et al. 2022

Psychiatry Clin Neurosci

Self Cite

View full text Add to dashboard Cite

Aim: Transcutaneous electrical cranial-auricular acupoint stimulation (TECAS) is a novel non-invasive therapy that stimulates acupoints innervated by the trigeminal and auricular vagus nerves. An assessor-blinded, randomized, noninferiority trial was designed to compare the efficacy of TECAS and escitalopram in mild-to-moderate major depressive disorder.Methods: 468 participants received two TECAS sessions per day at home (n = 233) or approximately 10-13 mg/day escitalopram (n = 235) for 8 weeks plus 4-week follow-up. The primary outcome was clinical response, defined as a baseline-to-endpoint ≥50% reduction in Montgomery-Åsberg Depression Rating Scale (MADRS) score. Secondary outcomes included remission rate, changes in the severity of depression, anxiety, sleep and life quality. Results:The response rate was 66.4% on TECAS and 63.2% on escitalopram with a 3.2% difference (95% confidence interval [CI], À5.9% to 12.9%) in intention-to-treat analysis, and 68.5% versus 66.2% with a 2.3% difference (95% CI, À6.9% to 11.4%) in per-protocol analysis. The lower limit of 95% CI of the differences fell within the prespecified non-inferiority margin of À10% (P ≤ 0.004 for non-inferiority). Most secondary outcomes did not differ between the two groups. TECAS-treated participants who experienced psychological trauma displayed a markedly greater response than those without traumatic experience (81.3% vs 62.1%, P = 0.013). TECAS caused much fewer adverse events than escitalopram.Conclusions: TECAS was comparable to escitalopram in improving depression and related symptoms, with high acceptability, better safety profile, and particular efficacy in reducing trauma-associated depression. It could serve an effective portable therapy for mild-to-moderate depression.

show abstract

Section: Figmentioning

confidence: 76%

mentioning

confidence: 99%

Transcutaneous electrical cranial‐auricular acupoint stimulation versus escitalopram for mild‐to‐moderate depression: An assessor‐blinded, randomized, non‐inferiority trial

Zhang

Yang

et al. 2022

Psychiatry Clin Neurosci

Self Cite

View full text Add to dashboard Cite

show abstract

“…Frontiers in Neurology 07 frontiersin.org diminishing stress and anxiety, and thus alleviating insomnia symptoms, facilitating both the initiation and maintenance of sleep (31).…”

Section: Discussionmentioning

confidence: 99%

“…As a vital component of the parasympathetic nervous system, the vagus nerve is instrumental in restoring balance between the sympathetic and parasympathetic nervous systems. Stimulation of the vagus nerve results in a reduced heart rate and blood pressure, contributing to a relaxed state, diminishing stress and anxiety, and thus alleviating insomnia symptoms, facilitating both the initiation and maintenance of sleep ( 31 ).…”

Section: Discussionmentioning

confidence: 99%

Efficacy of acupuncture therapy on cancer-related insomnia: a systematic review and network meta-analysis

Chen,

Li,

et al. 2024

Front. Neurol.

View full text Add to dashboard Cite

ObjectivesCancer-related insomnia (CRI) takes a toll on many cancer survivors, causing distressing symptoms and deteriorating the quality of life. Acupuncture therapy has been used for CRI already. However, it is still uncertain which acupuncture regime is best for CRI. The primary objective of this review is to conduct a comparative evaluation and ranking of the effectiveness of different acupuncture therapies for CRI.MethodsRandomized controlled trials (RCTs) that were published up to July 31, 2023, from 8 databases (PubMed, Embase, Cochrane library, Web of Science, China National Knowledge Infrastructure, Wanfang Database, VIP Database, and China Biology Medicine disc) were integrated in this study. Trials that met the inclusion criteria were evaluated the risk of bias. Pittsburgh sleep quality index (PSQI) was used to assess the efficacy of different acupuncture therapies as the primary outcome. Then, STATA 15, R, and OpenBUGS were applied to perform the network meta-analysis. PRISMA statements were followed in this network meta-analysis.ResultsA total of 37 studies were included in this review, involving 16 interventions with 3,246 CRI participants. Auriculotherapy + moxibustion [surface under the cumulative ranking curve (SUCRA) 98.98%] and auriculotherapy (SUCRA 77.47%) came out top of the ranking, which were more effective than control, medicine, usual care and sham acupuncture.ConclusionAuriculotherapy + moxibustion and auriculotherapy + acupuncture emerged as the top two acupuncture regimes for CRI and future studies should pay more attention to CRI.Clinical trial registrationhttps://clinicaltrials.gov/, identifier INPLASY202210095.

show abstract

“…Bai [22] 15-20 mA NS 30/60 Hz Maternal gastrointestinal function recovery Zusanli (ST36), Dubi (ST35) 30 min 13 Dong et al [23] Prefer patients to feel comfortable NS 2 Hz Insomnia Sanyinjiao (SP06), Neiguan (PC6), Shenmai (BL62), Zhaohai (KI6) 20 min 14 Chen et al [24] 5 mA NS 2/100 Hz Early functional rehabilitation after total knee arthroplasty Zusanli (ST36), Xuehai (SP10), Liangqiu (ST34), Yinlingquan (SP9), Yanglingquan (GB34), Weizhong (BL40) 30 min 15 Cao et al [25] 7-15 mA NS 10 Hz Delirium after total hip Joint replacement in the elderly Neiguan (PC6), Hegu (LI4) 30 min 16 Xia et al [26] The current intensity is tolerable by the patient 200 μs 100 Hz Apoplexy Jianyu (LI15), Quchi (LI11), Shousanli (LI10), Waiguan (SJ5) 20 min 17 Zhao et al [27] 0.5-2.0 mA 200 μs 4/20 Hz Depressive disorder with insomnia Baihui (GV20), Yintang (GV29), ear acupoints liver (CO 12 ), and heart (CO 15 )…”

Section: Ns 2 Hzmentioning

confidence: 99%

Review of transcutaneous electrical acupoint stimulation and related devices

Wang,

Zhang,

Feng

et al. 2024

Sci Tradit Chin Med

Self Cite

View full text Add to dashboard Cite

A review was undertaken of the operation process and development of transcutaneous electrical acupoint stimulation (TEAS) and related devices for TEAS, with the aim to offer a reference for developing an international standard for the basic safety and essential performance of the devices. The articles related to TEAS and instruction of devices for TEAS were searched using the EMBASE, MEDLINE, and Web of Science databases with the time period from inception to July 18, 2023. In the absence of a parameter description of the stimulators, a multimeter was used to measure the output voltage, resistance, and current. Thirty-two related devices for TEAS were obtained. The safety parameters of most devices were neither clearly defined, nor standardized, and in some cases were missing. There was a noticeable disparity in the upper safety limits of the output current among the devices. The sizes of the skin electrode pads as well as the lengths of the electrode connecting wires of most devices were not clearly indicated. Acupoints on different parts of the human body, including the upper limbs, head, auricle, chest, abdomen, trunk, and lower limbs, required different maximum tolerable current intensities and current densities. It is important to indicate comprehensive output/safety parameters and essential performance for devices for TEAS to meet the need of global distribution, achieve precise stimulation parameters at different acupoints across the human body, and allay any safety concern of national therapeutic device authorities, the regulators, manufacturers, and end users.

show abstract

Transcutaneous electrical cranial-auricular acupoints stimulation (TECAS) for treatment of the depressive disorder with insomnia as the complaint (DDI): A case series

Cited by 7 publications

References 9 publications

Transcutaneous electrical cranial‐auricular acupoint stimulation versus escitalopram for mild‐to‐moderate depression: An assessor‐blinded, randomized, non‐inferiority trial

Transcutaneous electrical cranial‐auricular acupoint stimulation versus escitalopram for mild‐to‐moderate depression: An assessor‐blinded, randomized, non‐inferiority trial

Efficacy of acupuncture therapy on cancer-related insomnia: a systematic review and network meta-analysis

Review of transcutaneous electrical acupoint stimulation and related devices

Contact Info

Product

Resources

About